None
Quote | Hansa Biopharma AB (OTCMKTS:HNSBF)
Last: | $2.93 |
---|---|
Change Percent: | 0.0% |
Open: | $2.93 |
Close: | $2.93 |
High: | $2.93 |
Low: | $2.93 |
Volume: | 150 |
Last Trade Date Time: | 03/14/2024 03:00:00 am |
News | Hansa Biopharma AB (OTCMKTS:HNSBF)
2024-07-18 13:17:06 ET Hansa Biopharma AB (publ) (HNSBF) Q2 2024 Results Conference Call July 18, 2024 08:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Hitto Kaufmann - Chief...
2024-07-18 12:49:30 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma Read the full article on Seeking Alpha For further details see: Hansa Biopharma Q2 GAAP EPS of -SEK3.30
Message Board Posts | Hansa Biopharma AB (OTCMKTS:HNSBF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting PR Newswire LUND , Sweden , May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be present...
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...